Related Experiment Video
Updated: Apr 7, 2026

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
Published on: June 8, 2018
Rewiring Metal-Dependent Cell Death to Unlock Immunotherapy in Colorectal Cancer
Ruyu Zhao1, Xinyue Wang1, Jiaqi Wang1
1State Key Laboratory of Flexible Electronics (LoFE) and Jiangsu Key Laboratory of Smart Biomaterials and Theranostic Technology, Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
Abstract:
Immune checkpoint blockade (ICB) shows limited efficacy in colorectal cancer (CRC), particularly in microsatellite-stable tumors characterized by an immunologically "cold" microenvironment. Notably, the high metabolic demand for copper and iron in CRC, together with metal overload-associated PD-L1 upregulation, makes cuproptosis and ferroptosis attractive targets to enhance ICB responsiveness. Here, we present a laser-activated lipid nanoplatform, CuFeS2-CA-DAC-Lipo (CCDL), that orchestrates cuproptosis, ferroptosis, and pyroptosis while remodeling the tumor immune microenvironment. CuFeS2 functions as a near-infrared II photothermal transducer and a source of copper and iron ions, inducing concurrent cuproptosis and ferroptosis via ion overload. Decitabine restores gasdermin E expression to couple oxidative stress with caspase-3-mediated pyroptosis, while chlorogenic acid repolarizes tumor-associated macrophages toward a pro-inflammatory phenotype. This coordinated multimodal cell-death cascade establishes a self-amplifying immunogenic circuit that suppresses tumor growth, sensitizes CRC to ICB, and elicits systemic antitumor immunity.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:03Author Spotlight: Understanding Cytokine-Induced Cell Death in Intestinal Epithelial Cells Using Human Organoids
Published on: August 2, 2024
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells